Multiomics and digital monitoring during lifestyle changes reveal independent dimensions of human biology and health.

P4 medicine lifestyle changes multiomics data integration personalized medicine precision health precision medicine systems medicine

Journal

Cell systems
ISSN: 2405-4720
Titre abrégé: Cell Syst
Pays: United States
ID NLM: 101656080

Informations de publication

Date de publication:
16 03 2022
Historique:
received: 11 02 2021
revised: 15 09 2021
accepted: 09 11 2021
pubmed: 3 12 2021
medline: 20 4 2022
entrez: 2 12 2021
Statut: ppublish

Résumé

We explored opportunities for personalized and predictive health care by collecting serial clinical measurements, health surveys, genomics, proteomics, autoantibodies, metabolomics, and gut microbiome data from 96 individuals who participated in a data-driven health coaching program over a 16-month period with continuous digital monitoring of activity and sleep. We generated a resource of >20,000 biological samples from this study and a compendium of >53 million primary data points for 558,032 distinct features. Multiomics factor analysis revealed distinct and independent molecular factors linked to obesity, diabetes, liver function, cardiovascular disease, inflammation, immunity, exercise, diet, and hormonal effects. For example, ethinyl estradiol, a common oral contraceptive, produced characteristic molecular and physiological effects, including increased levels of inflammation and impact on thyroid, cortisol levels, and pulse, that were distinct from other sources of variability observed in our study. In total, this work illustrates the value of combining deep molecular and digital monitoring of human health. A record of this paper's transparent peer review process is included in the supplemental information.

Identifiants

pubmed: 34856119
pii: S2405-4712(21)00451-8
doi: 10.1016/j.cels.2021.11.001
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

241-255.e7

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of interests O.K. received research funding from Vinnova for collaboration between Astra Zeneca, Takeda, Pelago, and Labcyte. O.K. is also a board member and a co-founder of Medisapiens and Sartar Therapeutics and has received a royalty on patents licensed by Vysis-Abbot. R.S. is currently employed at Crown CRO.

Auteurs

Francesco Marabita (F)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm 17165, Sweden. Electronic address: francesco.marabita@ki.se.

Tojo James (T)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm 17165, Sweden.

Anu Karhu (A)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland.

Heidi Virtanen (H)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland.

Kaisa Kettunen (K)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland; HUS Diagnostic Center, Division of Genetics and Clinical Pharmacology Laboratory of Genetics, University of Helsinki and Helsinki University Hospital, Helsinki 00029, Finland.

Hans Stenlund (H)

Science for Life Laboratory, Swedish Metabolomics Centre, Department of Plant Physiology, Umeå University, 90187 Umeå, Sweden.

Fredrik Boulund (F)

Science for Life Laboratory, Center for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 17165, Sweden.

Cecilia Hellström (C)

Science for Life Laboratory, Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, Stockholm 17165, Sweden.

Maja Neiman (M)

Science for Life Laboratory, Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, Stockholm 17165, Sweden.

Robert Mills (R)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland.

Teemu Perheentupa (T)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland.

Hannele Laivuori (H)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland; Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki 00029, Finland; Department of Obstetrics and Gynecology, Tampere University Hospital and Tampere University, Faculty of Medicine and Health Technology, Center for Child, Adolescent and Maternal Health Research, Tampere 33520, Finland.

Pyry Helkkula (P)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland.

Myles Byrne (M)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland.

Ilkka Jokinen (I)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland.

Harri Honko (H)

Faculty of Medicine and Health Technology, Tampere University, Tampere 33521, Finland.

Antti Kallonen (A)

Faculty of Medicine and Health Technology, Tampere University, Tampere 33521, Finland.

Miikka Ermes (M)

VTT Technical Research Centre of Finland, Espoo 02044, Finland.

Heidi Similä (H)

VTT Technical Research Centre of Finland, Espoo 02044, Finland.

Mikko Lindholm (M)

VTT Technical Research Centre of Finland, Espoo 02044, Finland.

Elisabeth Widén (E)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland.

Samuli Ripatti (S)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland; Public Health, Faculty of Medicine, University of Helsinki, Helsinki 00014, Finland; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Maritta Perälä-Heape (M)

Faculty of Medicine, University of Oulu, Oulu 90014, Finland; Centre for Health and Technology, University of Oulu, Oulu 90220, Finland.

Lars Engstrand (L)

Science for Life Laboratory, Center for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 17165, Sweden.

Peter Nilsson (P)

Science for Life Laboratory, Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, Stockholm 17165, Sweden.

Thomas Moritz (T)

Science for Life Laboratory, Swedish Metabolomics Centre, Department of Forest Genetics and Plant Physiology, Swedish University of Agricultural Sciences, Umeå 90187, Sweden; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark.

Timo Miettinen (T)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland.

Riitta Sallinen (R)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm 17165, Sweden.

Olli Kallioniemi (O)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki 00290, Finland; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm 17165, Sweden. Electronic address: olli.kallioniemi@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH